Last reviewed · How we verify
The fourth dose
At a glance
| Generic name | The fourth dose |
|---|---|
| Sponsor | BioSyngen Pte Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes (PHASE1)
- Comparison of the Analgesic Efficacy of Chest Wall Blocks in Coronary Artery Bypass Surgery (NA)
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (PHASE1, PHASE2)
- Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
- Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing (PHASE2)
- LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer (PHASE2)
- Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients (NA)
- PS-002 for the Treatment of IgA Nephropathy in Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The fourth dose CI brief — competitive landscape report
- The fourth dose updates RSS · CI watch RSS
- BioSyngen Pte Ltd portfolio CI